Cell Lines* Derived from NK-Cell Neoplasm Used in This Study

Supplemental Table 1: Cell lines included in this study

ANKL: aggressive NK-cell leukemia; ENKL: extranodal NK-cell lymphoma; CAEBV: chronic active EBV infection; T-ALL: T-cell acute lymphoblastic leukemia

*Sources of cell line: Four cell lines were provided by Dr Norio Shimuzu (SNK-1, SNK10 and SNK-61; NK-YS2). YT3 and NK-924 were obtained from the German Collection of Microorganism and Cell Culture(GCMCC) ( DSMZ, Braunschweig, Germany). IMC-15, KHYG1 6 , KAI3 7 were obtained from the Health Science Research Resource (Osaka, Japan). The gd T-cell lines (SNT13, SNT15 and SNT8)1 were obtained from Dr Norio Shimuzu. These cell lines are CD4- CD8- and express TCRgd. The other T-cell lines (JURKAT, MOLT-3, and PEER) and the cutaneous T- cell line (HUT78) were obtained from GCMCC.

Supplemental Table 2: Differentially-expressed genes between molecularly defined gd-PTCL (NHS) and NK-cell lineage malignancies

** The 25- most significant (p-value) differentially up- and down-regulated transcripts are included

Supplemental Table 3: gd-PTCL (NHS), gd ENKTL and HSTCL: Clinical characteristics, Immunophenotype and EBV status

gd-PTCL (NHS)

NA: Not available, LN: Lymph node, PTCL-NOS: Peripheral T-cell lymphoma, not otherwise specified, EATCL: Enteropathy associated T-cell lymphoma, ENKTL: extra-nodal NK/T-cell lymphoma, nasal type;

* Originally called as PTCL-NOS (2001 WHO classification), but could be classified as cutaneous gd- PTCL by 2008 WHO classification

HSTCL

IND: indeterminant, HSTCL: hepatosplenic T-cell lymphoma

**Iso 7q was identified in HS1, HS3 and HS4, consistent with HSTCL

Supplemental Table 4: Differentially-expressed genes between molecularly defined HSTCL and NK-cell lineage malignancies

Supplemental Table 5: Differentially-expressed genes between molecularly defined CT (αb)-PTCL and NK-cell lineage malignancies

Supplemental Table 6: Differentially-expressed genes between molecularly defined gd-PTCL (NHL) and CT (αb)-PTCL

Supplemental reference

1. Nagata H, Konno A, Kimura N, et al. Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood. 2001;97:708-713.

2. Tsuge I, Yoshino T, Mori M, Kondoh E, Oka T, Matsuoka H. Characterization of a novel human natural killer (NK) cell proliferation in patients with Epstein-Barr virus infection. Blood. 1998;92:385-392.

3. Gong J, Maki G, Nikaido T. Characterization of a human cell line (YT cells. Leukemia. 1985;8:652-658.

4. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8:652-658.

5. Chen IM, Whalen M, Bankhurst A, et al. A new human natural killer leukemia cell line, IMC-1. A complex chromosomal rearrangement defined by spectral karyotyping: functional and cytogenetic characterization. Leuk Res. 2004;28:275-284.

6. Yagita M, Huang CL, Umehara H, et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia. 2000;14:922-930.

7. Tsuge I, Morishima T, Morita M, Kimura H, Kuzushima K, Matsuoka H. Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line. Clin Exp Immunol. 1999;115:385-392.